• Energy Research
• Open Access close
• Restricted close
• Embargo close
• US close
• AU close

These data include population fitness measurements collected for Acartia hudsonica during multigenerational exposure to ocean warming (OW), ocean acidification (OA), and combined ocean warming and acidification (OWA) including a benign ambient condition temperature and CO2 control (AM).

The atmosphere concentration of CO2 is steadily increasing and causing climate change. To achieve the Paris 1.5 or 2 oC target, negative emissions technologies must be deployed in addition to reducing carbon emissions. The ocean is a large carbon sink but the potential of marine primary producers to contribute to carbon neutrality remains unclear. Here we review the alterations to carbon capture and sequestration of marine primary producers (including traditional ‘blue carbon’ plants, microalgae, and macroalgae) in the Anthropocene, and, for the first time, assess and compare the potential of various marine primary producers to carbon neutrality and climate change mitigation via biogeoengineering approaches. The contributions of marine primary producers to carbon sequestration have been decreasing in the Anthropocene due to the decrease in biomass driven by direct anthropogenic activities and climate change. The potential of blue carbon plants (mangroves, saltmarshes, and seagrasses) is limited by the available areas for their revegetation. Microalgae appear to have a large potential due to their ubiquity but how to enhance their carbon sequestration efficiency is very complex and uncertain. On the other hand, macroalgae can play an essential role in mitigating climate change through extensive offshore cultivation due to higher carbon sequestration capacity and substantial available areas. This approach seems both technically and economically feasible due to the development of offshore aquaculture and a well-established market for macroalgal products. Synthesis and applications: This paper provides new insights and suggests promising directions for utilizing marine primary producers to achieve the Paris temperature target. We propose that macroalgae cultivation can play an essential role in attaining carbon neutrality and climate change mitigation, although its ecological impacts need to be assessed further. To calculate the parameters presented in Table 1, the relevant keywords "mangroves, salt marshes, macroalgae, microalgae, global area, net primary productivity, CO2 sequestration" were searched through the ISI Web of Science and Google Scholar in July 2021. Recent data published after 2010 were collected and used since area and productivity of plants change with decade. For data with limited availability, such as net primary productivity (NPP) of seagrasses and global area and NPP of wild macroalgae, data collection was extended back to 1980. Total NPP and CO2 sequestration for mangroves, salt marshes, seagrasses and wild macroalgae were obtained by the multiplication of area and NPP/CO2 sequestration density and subjected to error propagation analysis. Data were expressed as means ± standard error.

Monthly and daily summary from the Fortuna Station (Centro de Investigaciones Jorge L. Arauz)Location: 8° 43.340'N, 82° 14.241'WParameters: air temperature, wind speed and direction, precipitation, solar radiation (pyranometer)Located in the highlands of the Chiriqui Province, in western Panama.There are three sensor locations: north clearing, south clearing, and a 15m tower.

This dataset contains the underlying data for the following publication: Doukas, H., Spiliotis, E., Jafari, M. A., Giarola, S. & Nikas, A. (2021). Low-cost emissions cuts in container shipping: Thinking inside the box. Transportation Research Part D: Transport and Environment, 94, 102815, https://doi.org/10.1016/j.trd.2021.102815.

Approximately 11,000 Veterans present to a VAMC annually with an acute ischemic stroke or TIA. The cornerstone of secondary stroke/TIA prevention includes delivering timely, guideline-concordant vascular risk factor management. Over the past decade, OSA has been recognized as a potent, underdiagnosed, and inadequately treated cerebrovascular risk factor. OSA is very common among patients with stroke/TIA with a prevalence of 70-80%. Despite being highly prevalent, 70-80% of patients with OSA are neither diagnosed nor treated. Untreated OSA has been associated with poor outcomes among patients with cerebrovascular disease including higher mortality and worse functional status. The mainstay of OSA therapy is positive airway pressure (PAP). PAP reduces recurrent vascular events, improves neurological symptoms and functional status among stroke/TIA patients with OSA. The evidence favoring neurological recovery is strongest when interventions are applied early post-stroke/TIA. Guidelines recommend diagnosing and treating OSA for stroke and TIA patients; however, within VHA, very few stroke or TIA patients receive OSA screening. This guideline recommendation was informed in part by clinical trials utilizing an acute OSA assessment protocol developed and implemented by the investigators' group. To address the observed gap in care, the investigators propose a Hybrid Type I, randomized, stepped-wedge trial at 6 VAMCs to increase the rate of timely, guideline-concordant diagnosis and treatment of OSA among Veterans with ischemic stroke/TIA and thereby reduce recurrent vascular events and hospital readmissions. The investigators will identify matched control sites for each ASAP implementation site to examine temporal trends in outcomes among non-intervention sites. For example, the investigators will use administrative data to examine the use of polysomnography across stroke/TIA patients in the VA system and compare changes in matched controls versus the intervention sites on the diagnostic rate. The same adjustment approach will be used for ASAP intervention sites and for control sites. Effectively identifying and treating risk factors for ischemic stroke and transient ischemic attack (TIA) is important to patients, their family members, and healthcare systems. While obstructive sleep apnea (OSA) is a known risk factor for stroke and TIA that is present in more than 70% of stroke/TIA survivors, testing for OSA is infrequently performed for patients and within healthcare systems. The Addressing Sleep Apnea Post-Stroke/TIA (ASAP) study intends to improve rates of guideline-recommended OSA testing and treatment through local quality improvement initiatives (QI) conducted within and across 6 VA Medical Centers. ASAP will also determine the impact of these local QI initiatives on rates of OSA diagnosis, OSA treatment, treatment adherence, recurrent vascular events, and hospital readmissions.